What one share of Mosaic Immunoengineering holds
We are a development-stage biotechnology company focused on advancing and eventually commercializing immunotherapies for the treatment of cancer. We have historically advanced early-stage product candidates and we are pursuing new product candidates and platforms to build a product pipeline based on our deep understanding of immunotherapies.
Mosaic Immunoengineering’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.10 |
|---|---|
| Cash and investments | $0.00 |
| Book value | −$1.08 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2021 | — | −$0.55 | — | — | — | −$0.39 |
| 2022 | — | −$0.33 | — | — | — | −$0.67 |
| 2023 | — | −$0.14 | — | — | — | −$0.81 |
| 2024 | — | −$0.13 | — | — | — | −$0.94 |
| 2025 | — | −$0.10 | — | — | — | −$1.03 |
Common questions about Mosaic Immunoengineering
How much does one share of Mosaic Immunoengineering earn?
Over the last 12 months, Mosaic Immunoengineering lost $0.10 for each share.
Does Mosaic Immunoengineering pay a dividend?
Mosaic Immunoengineering didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Mosaic Immunoengineering’s book value per share?
Mosaic Immunoengineering’s book value is negative (−$1.08 per share): it owes more than everything it owns is recorded at, often after years of buying back its own shares, as of June 30, 2026.
How much cash and debt does each share of Mosaic Immunoengineering have?
Each share of Mosaic Immunoengineering has $0.00 of cash and investments, as of June 30, 2026.
Has Mosaic Immunoengineering bought back shares?
Mosaic Immunoengineering’s share count rose about 8% from 2021 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.